January 19, 2025
Abstract Background Risk estimation is an essential component of cardiovascular disease prevention among people with HIV. We aimed to characterise how well atherosclerotic cardiovascular disease (ASCVD) […]
December 11, 2024
Abstract Importance In a mechanistic substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) randomized clinical trial, pitavastatin reduced noncalcified plaque (NCP) volume, but […]
October 11, 2024
Abstract Background: Among people with HIV (PWH), COVID-19 is common and potentially severe. We leveraged REPRIEVE to assess the effects of statin therapy for cardiovascular disease […]
October 8, 2024
Abstract Background: REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) led to new guidelines for statin use among people with HIV (PWH) with low to […]
October 7, 2024
Abstract Objectives: To determine baseline prevalence of proteinuria and albuminuria among REPRIEVE participants and evaluate associated risk factors. Design: Cross sectional analysis of a baseline sample of participants […]
August 28, 2024
Abstract Background: Little is known about the potential benefits or harms of statins on physical function among people with HIV (PWH). Methods: REPRIEVE was a double-blind randomized controlled […]
August 28, 2024
Abstract Background Coronary plaque is common among people with HIV (PWH) with low-to-moderate traditional atherosclerotic cardiovascular disease (ASCVD) risk. Objectives The purpose of this study was […]
May 2, 2024
Abstract The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) (Aug. 24 issue of NEJM) was a global trial that assessed pitavastatin calcium as compared […]
May 2, 2024
Abstract Background People with HIV (PWH) have a high burden of coronary plaques; however, the comparison to people without known HIV (PwoH) needs clarification. Objectives The […]
January 19, 2025
Abstract Background Risk estimation is an essential component of cardiovascular disease prevention among people with HIV. We aimed to characterise how well atherosclerotic cardiovascular disease (ASCVD) […]
December 11, 2024
Abstract Importance In a mechanistic substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) randomized clinical trial, pitavastatin reduced noncalcified plaque (NCP) volume, but […]
October 11, 2024
Abstract Background: Among people with HIV (PWH), COVID-19 is common and potentially severe. We leveraged REPRIEVE to assess the effects of statin therapy for cardiovascular disease […]
October 8, 2024
Abstract Background: REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) led to new guidelines for statin use among people with HIV (PWH) with low to […]
October 7, 2024
Abstract Objectives: To determine baseline prevalence of proteinuria and albuminuria among REPRIEVE participants and evaluate associated risk factors. Design: Cross sectional analysis of a baseline sample of participants […]
August 28, 2024
Abstract Background: Little is known about the potential benefits or harms of statins on physical function among people with HIV (PWH). Methods: REPRIEVE was a double-blind randomized controlled […]
August 28, 2024
Abstract Background Coronary plaque is common among people with HIV (PWH) with low-to-moderate traditional atherosclerotic cardiovascular disease (ASCVD) risk. Objectives The purpose of this study was […]
May 2, 2024
Abstract The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) (Aug. 24 issue of NEJM) was a global trial that assessed pitavastatin calcium as compared […]
May 2, 2024
Abstract Background People with HIV (PWH) have a high burden of coronary plaques; however, the comparison to people without known HIV (PwoH) needs clarification. Objectives The […]